By Dean Seal

Verastem Oncology said federal regulators have granted their fast-track designation to a combination of the company's avutometinib with Amgen's sotorasib for the treatment of non-small cell lung cancer.

The Boston-based biopharmaceutical company said the special status from the Food and Drug Administration will fast-track the development of the combination for patients with KRAS G12C-mutant metastatic non-small cell lung cancer who have received at least one prior systemic therapy and haven't previously been treated with a KRAS G12C inhibitor.

The FDA's fast-track designation facilitates development and expedites the review of drugs that treat serious or life-threatening conditions and fill unmet medical needs.

"Given that KRAS G12C is the most common KRAS mutation in NSCLC, the advancement of the combination is important in understanding potential new treatment approaches," Chief Executive Dan Paterson said.

Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

01-18-24 1631ET